Want to see KR:004720 full AI Analyst Report?
PharmGen Science, Inc. (004720) AI Stock Analysis
PharmGen Science, Inc.
(Korea Exchange:004720)
The score is primarily held back by the sharp swing to very large net losses and weak technical trend (price below all key moving averages with negative MACD). Offsetting factors include a conservatively levered balance sheet and improved TTM operating/free cash flow, but valuation is constrained by negative earnings and no provided dividend yield.
PharmGen Science, Inc. (004720) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 62.52B
- Dividend Yield
- ―
- Average Volume (3M)
- 17.96K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- -0.04
- Revenue Growth
- 0.42%
- EPS Growth
- -4001.63%
- Country
- KR
- Employees
- 229
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - General
PharmGen Science, Inc. Business Overview & Revenue Model
Company Description
PharmGen Science, Inc., originally founded in 1961 as Wooridul Pharmaceutical Limited, is a South Korean company primarily involved in the research, development, manufacturing, and distribution of pharmaceutical products. Based in Hwaseong, South Kor...
PharmGen Science, Inc. Financial Statement Overview
Summary
Balance sheet strength and low leverage support resilience (Balance Sheet Score: 72), and operating/free cash flow improved in TTM (Cash Flow Score: 62). However, profitability deteriorated sharply with very large net losses in 2025 and TTM despite positive EBIT/EBITDA (Income Statement Score: 32), raising earnings quality and volatility concerns.
Income Statement
32NegativeBalance Sheet
72PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.36B | 173.07B | 171.29B | 166.78B | 150.93B | 109.87B |
| Gross Profit | 112.69B | 109.13B | 108.03B | 96.20B | 81.30B | 60.80B |
| EBITDA | 8.59B | 10.53B | 10.79B | 13.37B | 10.78B | -254.11M |
| Net Income | -134.36B | -116.64B | 2.79B | 5.73B | 70.06B | 32.47B |
Balance Sheet | ||||||
| Total Assets | 184.19B | 195.41B | 363.45B | 335.92B | 317.39B | 220.32B |
| Cash, Cash Equivalents and Short-Term Investments | 20.05B | 22.41B | 38.45B | 37.44B | 19.89B | 34.19B |
| Total Debt | 698.13M | 6.00B | 38.99B | 37.96B | 39.49B | 48.01B |
| Total Liabilities | 44.15B | 49.11B | 114.02B | 107.71B | 110.28B | 93.39B |
| Stockholders Equity | 140.04B | 146.30B | 249.44B | 228.22B | 207.12B | 126.94B |
Cash Flow | ||||||
| Free Cash Flow | 14.94B | 3.86B | -399.26M | 2.15B | -13.24B | -26.23B |
| Operating Cash Flow | 17.33B | 5.32B | 2.38B | 5.44B | -1.29B | 7.78B |
| Investing Cash Flow | -7.60B | -2.42B | -889.45M | 3.26B | -15.28B | -30.39B |
| Financing Cash Flow | -2.86B | -18.93B | -483.95M | 8.85B | 2.27B | 30.34B |
PharmGen Science, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:004720, the sentiment is Negative. The current price of 2765.00 is below the 20-day moving average (MA) of 2799.75, below the 50-day MA of 2952.50, and below the 200-day MA of 3471.28, indicating a bearish trend. The MACD of -55.37 indicates Negative momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 71.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:004720.
PharmGen Science, Inc. Peers Comparison
Overall Rating
KR:00309062Neutral- KR:00472050Neutral
KR:18349049Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:003090 | 62Neutral | KRW 617.86B | 3.25 | ― | 1.32% | 4.55% | 116.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:004720 | 50Neutral | KRW 62.52B | -0.45 | ― | ― | 0.42% | -4001.63% |
| KR:183490 | 49Neutral | KRW 76.86B | -8.16 | ― | ― | -5.10% | 19.68% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:004720 | PharmGen Science, Inc. | 2765.00 | -1125.00 | -28.92% | |
| KR:003090 | Daewoong Co., Ltd. | 15110.00 | -6496.22 | -30.07% | |
| KR:032300 | KOREA PHARMA Co., Ltd. | 7770.00 | -5319.54 | -40.64% | |
| KR:036220 | Osang Healthcare Co. Ltd. | 5090.00 | -7367.41 | -59.14% | |
| KR:175250 | Icure Pharmaceutical Incorporation | 1530.00 | -640.00 | -29.49% | |
| KR:183490 | Enzychem Lifesciences Corp. | 990.00 | -1.00 | -0.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026